Dr Richard Mason becomes ceo
Dr Richard Mason has joined 4-Antibody AG as ceo from venture capital firm Advent Venture Partners, an investor in 4-Antibody, where he has been an executive-in-residence.
Dr Richard Mason has joined 4-Antibody AG as ceo from venture capital firm Advent Venture Partners, an investor in 4-Antibody, where he has been an executive-in-residence.
Previously, Mason was senior vice president business development at Cambridge Antibody Technology plc (CAT). As head of CAT's business development team he was responsible for numerous transactions with major pharmaceutical and biotechnology companies including leading the negotiation of the original antibody co-discovery and co-development agreement with AstraZeneca which subsequently led to AstraZeneca's acquisition of CAT for $1.3bn.
"We are delighted to appoint Richard as our CEO to lead 4-Antibody through the next exciting phase of its growth. His organisational leadership skills and experience in commercial dealmaking in the antibody space will be instrumental as we establish our technology as a new gold standard for the discovery of fully human monoclonal antibody therapeutics" said Prof. Dr. Max Burger, chairman of 4-Antibody's Board.
